25 results about "Angiogenesis Effect" patented technology

The invention provides human placenta-derived vasogenic stem cells (hPASCs) and application thereof. The human placenta-derived angiogenic stem cells (hPASCs) disclosed by the invention are preserved in China Center for Type Culture Collection, Wuhan University, Wuhan, China; the preservation date is April 2, 2025; the preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: The hPASCs disclosed by the invention contain angiogenic cell subgroups, have stem cell stemness, have an angiogenesis effect in vivo and in vitro, and can be used for treatment of diseases such as cardiovascular diseases and vascularization construction of artificial organs and tissues.

The invention discloses a visual multifunctional injectable hydrogel with endogenous and endogenous stimulation responsiveness as well as a preparation method and application of the visual multifunctional injectable hydrogel. The hydrogel is mainly prepared from oxygen vacancy molybdenum oxide nanoparticles Ce6-coated PEG-MoOx, transglutaminase and gelatin, wherein the oxygen vacancy molybdenum oxide nanoparticles Ce6-coated PEG-MoOx are loaded with a photosensitizer chlorin e6 and are modified by polyethylene glycol. The hydrogel disclosed by the invention can be applied to preparation of anti-inflammatory, anti-infection or wound repair promoting medicines, especially medicines for treating periodontitis or oral infection. The visible multifunctional injectable hydrogel with endogenous and endogenous stimulus responsiveness, which is constructed by the invention, can be developed through photoacoustic imaging, can play a role of a contrast agent, presents a morphological structure of an area in which the hydrogel is located, can eliminate negative oxidative stress of tissues, can efficiently and quickly kill bacteria, and can be used for preparing a medical dressing for treating endogenous and endogenous stimulus responsiveness. The inorganic signal molecules are controlled in a long-acting and controlled-release manner to play anti-inflammatory and angiogenesis promoting roles, so that tissue healing is promoted.

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

The invention discloses a double-layer GBR membrane for promoting soft and hard tissue repair and a preparation method and application thereof, and is applied to the field of medical materials. The double-layer GBR membrane mainly comprises an acellular dermal matrix obtained by decellularizing fetal calfskin and a piezoelectric layer prepared by electrostatic spinning of poly-L-lactic acid and chitosan, and the acellular dermal matrix and the piezoelectric layer are further combined through a polydopamine coating prepared on the surface of the piezoelectric layer. During application, the acellular dermal matrix side faces the soft tissue side, and the piezoelectric layer faces the bone tissue side, so that the acellular dermal matrix skin side which is compact in structure is in contact with the soft tissue to play a barrier role, and the relatively loose piezoelectric layer is in contact with bone defects to play a role in guiding osteoblasts to adhere; functionally, soft tissue repair is promoted through the angiogenesis promoting effect of the acellular dermal matrix and the similarity of the tissue of the acellular dermal matrix, and bone regeneration of a bone defect area is promoted through the piezoelectric osteogenesis and angiogenesis effects of the piezoelectric layer.

The invention discloses a gel for preventing radiodermatitis. According to the invention, firstly, iNOS-DNA enzyme is designed, and the nucleotide sequence of the iNOS-DNA enzyme is shown as SEQ ID NO.1; the preparation method comprises the following steps: dissolving iNOS-DNA enzyme and cobalt nitrate in methanol to obtain a solution A, and dissolving dimethylimidazole in methanol to obtain a solution B; the solution A and the solution B are mixed and stirred, and iNOS-DZ-ZIF-67 is obtained; the preparation method comprises the following steps: dissolving hyaluronic acid in a sodium acetate solution to obtain a hyaluronic acid (HA) solution, adding iNOS-DZ-ZIF-67 / HA into the hyaluronic acid (HA) solution, stirring in a dark place, freeze-drying and precipitating, and adding water and mixing when in use to obtain the gel for preventing radiodermatitis. The prepared gel has good stability, slow release property and angiogenesis effect, the delivery rate and antibacterial property can be improved, and radiodermatitis can be prevented and treated in a targeted mode.

The invention relates to application of Lignicol in preparation of a product for preventing or treating ischemic diseases, and belongs to the technical field of biological medicines. The invention discovers that Lignicol has the effect of treating ischemic diseases, such as ischemic cardiovascular diseases, ischemic cerebrovascular diseases, limb ischemic diseases, peripheral artery occlusion diseases and the like, for the first time. The application of zebra fish as experimental animal detection finds that Lignicol can effectively relieve vascular injury caused by Vatalanib base (PTK787) in an organism, has a remarkable angiogenesis promoting effect, can be applied to treatment of ischemic diseases, and is small in toxic and side effects. The invention can provide candidates for drugs for treating ischemic diseases, and has wide market prospects.

The invention relates to an anti-cancer composition based on natural active ingredients and a medicine thereof, and belongs to the technical field of medicine compositions. The anticancer composition based on the natural active ingredients is prepared from the following components in percentage by mass: 1 to 10 percent of ginsenoside Rg3, 5 to 20 percent of dihydroquercetin, 20 to 40 percent of lucid ganoderma extract, 15 to 30 percent of astragalus extract and 15 to 30 percent of coix seed extract. In the anti-cancer composition based on the natural active ingredients, ginsenoside Rg3 has the effect of inhibiting tumor angiogenesis; the dihydroquercetin has remarkable antioxidant and anti-inflammatory activity; ganoderma lucidum polysaccharide can enhance the immune function of the body. Astragaloside has an immunoregulation effect; coix seed ester has the anti-tumor metastasis activity, the anti-cancer effect is remarkably enhanced through the synergistic effect of multiple components, toxic and side effects are low, the composition is suitable for long-term taking, and the product quality is stable.

The invention discloses a preparation method of CEFFE-loaded double-layer hydrogel applied to clinical postoperative pancreatic fistula. The invention develops asymmetric double-layer hydrogel (Ceffe-coated BH) comprising an adhesion pancreatic layer (APL) and an anti-adhesion layer (AAL). The adhesion pancreatic layer is combined with the interface dehydration capability of N-hydroxysuccinimide (NHS) mediated covalent bonds and xanthan gum (XG) to realize strong wet tissue adhesion, and the anti-adhesion layer is composed of poly (sulfobetaine methacrylate)-carboxymethyl chitosan (PSBMA-CMCS) to prevent fibrosis through surface hydration. The double-layer hydrogel has excellent mechanical strength and relatively long adhesion after swelling and anti-enzyme activity. The cell-free fat extract (Cffe) is added into the double-layer hydrogel, so that the anti-inflammatory and angiogenesis promoting effects are realized, and the pancreatic stump healing is further enhanced.

The present invention relates to the angiogenesis agent containing a mesenchymal stem cell-derived extracellular vesicle, as an active ingredient, in which an extracellular vesicle is obtained by a method of using a substance that contains an extracellular vesicle having an affinity for phosphatidylserine, or / and an extracellular vesicle is derived from a mesenchymal stem cell stimulated with a growth factor, and relates to a method of producing an extracellular vesicle as the angiogenesis agent.

The application is a kind of nanoscale enzyme multifunctional composite hydrogel and its preparation method and application, belonging to the field of biological medicine technology. In view of the problem that the existing materials or drugs have poor treatment effect on infected wound, the application comprises the following steps: preparing solution A and solution B respectively, standby, preparing Cu-TCPP-Mn nanosheet, obtaining Cu-TCPP-Mn nanodot after further treatment, adding the activated Cu-TCPP-Mn nanodot into solution A to obtain mixed solution C with a concentration of 5 mu g / mL, adding the activated PRP solution into solution B to obtain mixed solution D with a concentration of 100 mu g / mL, and mixing the mixed solution C and the mixed solution D in equal volume to obtain CHPM composite hydrogel. The CHPM composite hydrogel can effectively reduce the oxidative stress level of acute infected wound tissue, provide a suitable oxidative microenvironment for PRP to play a role in promoting angiogenesis, and accelerate the healing of acute infected wound.

The application provides a nucleic acid molecule, a pro-angiogenic mesenchymal stromal cell and application thereof, relates to the biomedical technical field, and the nucleic acid molecule encodes HGF protein, or encodes VEGF165 protein and HGF protein; a first signal peptide is used as the signal peptide of the VEGF165 protein, and a second signal peptide is used as the signal peptide of the HGF protein. Through a gene modification strategy, MSC cells containing the nucleic acid molecule can stably and efficiently express VEGF165 and / or HGF, and the expression amount is significantly higher than that of MSC without the nucleic acid molecule. The cells have the ability to promote the migration of endothelial cells; meanwhile, the cells can also significantly promote the proliferation and tube formation of HUVEC cells, and further confirm the strong pro-angiogenic effect. The technical problem that nucleic acid molecules expressing VEGF165 or / HGF cannot be stably and efficiently expressed in the prior art is solved.

The invention discloses application of TPM1 in treatment of wet age-related macular degeneration. Research finds that TPM1 promotes angiogenesis, inflammation and fibrosis in eyes. The anti-angiogenesis effect of inhibiting TPM1 is similar to that of inhibiting VEGF-A, but the effect of inhibiting TPM1 is more remarkable in the aspect of reducing inflammation and fibrosis, so that the compound can be used as a potential target for treating wAMD. In addition, single cell sequencing finds that the TPM1 has high specific expression in CNV focus peripheral cells of a wAMD patient; functional experiments prove that the TPM1 is knocked down to significantly inhibit periodontocyte proliferation and migration, which prompts that the TPM1 participates in wAMD progress by regulating periodontocyte functions and does not respond to anti-VEGF treatment.

The invention discloses a double natural drug loaded separable microneedle patch, which comprises a microneedle tip array layer prepared from a polylactic acid-glycolic acid copolymer loaded with rare ginsenoside Rk3 and diallyl trisulfide, and a separable backing layer connected to the back of the microneedle tip array layer, and the separable backing layer is prepared from polyvinyl alcohol and polyvinylpyrrolidone. In addition, the invention further discloses a preparation method and application of the separable microneedle patch loaded with the double natural drugs. According to the invention, Rk3 and DATS are cooperatively loaded in the PLGA microneedle, so that the effects of immunoregulation and angiogenesis promotion are exerted, the problems of local immune imbalance and tissue perfusion disorder in CLI treatment are remarkably improved, and anti-inflammatory and vascular remodeling dual-targeting combined treatment is realized.

The invention discloses a ring-opening selenine-like organic selenium compound as well as a preparation method and application thereof, and relates to the field of medicinal chemistry. The 11 ring-opening selenine-like organic selenium compounds with novel structural characteristics are successfully synthesized, the synthesis method is simple and convenient, the reaction condition is mild, the yield is high, and the method is suitable for industrial production. Experiments show that the compounds have the following advantages: 1) the toxicity is low, the safety is good, and the effective action concentration is far lower than a toxicity threshold value; 2) the anti-tumor activity is remarkable, an excellent inhibition effect is shown on esophageal cancer, lung cancer, liver cancer, colon cancer and breast cancer, the inhibition rates of the compound 11 on KYS30 and A549 cells at the concentration of 10 mu M are 75% and 85% or above respectively, and the IC50 value is remarkably lower than that of a control drug fumagillin; and 3) in a zebra fish model, the subintestinal blood vessel area and the number of internode blood vessels can be obviously reduced, which indicates that the compound has an anti-angiogenesis effect. The compound disclosed by the invention has important application value in the aspect of preparing anti-tumor and anti-angiogenesis medicines.

The invention discloses a medicine carrying balloon catheter system which comprises a balloon body, the balloon body has a relative inflation state and a contraction state suitable for interventional conveying, and the balloon wall of the balloon body is provided with a pore structure. A coating containing a first active cross-linking agent and a water-soluble slow-release layer wrapping the coating are loaded on the outer wall of the balloon body; the catheter is provided with a far end and a near end which are opposite to each other, and the far end is communicated with the balloon body; the perfusion device is used for supplying a second active cross-linking agent into the balloon body in a fluid manner through the near end of the catheter; and the light source device is used for applying illumination to the first active cross-linking agent and the second active cross-linking agent. By means of the drug-loading balloon catheter system, the angiogenesis effect can be improved.

The invention relates to nano-enzyme-loaded multifunctional composite hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. In order to solve the problem that an existing material or medicine is poor in treatment effect on infected wounds, the preparation method comprises the steps that a solution A and a solution B are prepared for standby application, Cu-TCPP-Mn nanosheets are prepared, Cu-TCPP-Mn nanodots are obtained after further treatment, the activated Cu-TCPP-Mn nanodots are added into the solution A, a mixed solution C with the concentration of 5 micrograms / mL is obtained, an activated PRP solution is added into the solution B, and the mixed solution C is mixed with the activated PRP solution to obtain a mixed solution C with the concentration of 5 micrograms / mL; mixing the mixed solution C with the mixed solution D in an isovolumetric manner, so as to obtain the CHPM composite hydrogel. The CHPM composite hydrogel disclosed by the invention can effectively relieve the oxidative stress level of acute infection wound tissues, provides a proper oxidation microenvironment for PRP to play a role in promoting angiogenesis, and accelerates healing of acute infection wounds.

The invention discloses a medicine carrying balloon catheter system which comprises a balloon body, the balloon body has a relative inflation state and a contraction state suitable for interventional conveying, and the balloon wall of the balloon body is provided with a pore structure. A coating containing a first active cross-linking agent and a water-soluble slow-release layer wrapping the coating are loaded on the outer wall of the balloon body; the catheter is provided with a far end and a near end which are opposite to each other, and the far end is communicated with the balloon body; the perfusion device is used for supplying a second active cross-linking agent into the balloon body in a fluid manner through the near end of the catheter; and the light source device is used for applying illumination to the first active cross-linking agent and the second active cross-linking agent. By means of the drug-loading balloon catheter system, the angiogenesis effect can be improved.

The invention relates to a metal polyphenol network coated salvia miltiorrhiza extracellular vesicle nanoparticle as well as a preparation method and application thereof, and aims to provide a metal polyphenol network coated salvia miltiorrhiza extracellular vesicle nanoparticle which has the effects of resisting inflammation, resisting oxidation and promoting angiogenesis and has good photo-thermal performance. The Salvia miltiorrhiza extracellular vesicles are soaked by coating Salvia miltiorrhiza extracellular vesicles with a metal polyphenol network prepared from Salvia miltiorrhiza source extracellular vesicles, gallic acid and ruthenium trichloride, and the Salvia miltiorrhiza extracellular vesicles belong to the technical field of biomedicine.

The invention relates to an HDAC6 (histone deacetylase 6) and HIF-1alpha inhibitor and application of a pharmaceutically acceptable salt thereof in preparation of a multifunctional object, and the structure of the HDAC6 and HIF-1alpha inhibitor is shown as a formula I or a formula II. The HDAC6 and HIF-1alpha inhibitor and the pharmaceutically acceptable salt thereof have the structural formula shown in the description. The pharmacodynamic action molecular mechanism is that a plurality of signal channels related to double-target downstream anti-tumor synergism and formed multifunctional combined synergism are realized, and the action mechanism is novel. The compound further has breast cancer proliferation, metastasis and angiogenesis resisting effects equivalent to or stronger than those of positive control drugs panobinostat and sorafenib, and has tumor immunosuppression and immune escape reversing effects, so that the compound is expected to realize similar effects of clinical cocktail therapy; and toxic and side effects increased by combined application of a plurality of chemotherapeutic drugs are avoided.

The invention discloses application of ginsenoside Rb1 in preparation of a medicine for delaying development of acute kidney injury to chronic kidney disease. Through the technical scheme of the invention, the ginsenoside Rb1 can improve the renal function and pathological injury in the AKI-CKD period, promote kidney angiogenesis, improve vasodilation, improve the angiogenesis effect and vasodilation function of HUVEC induced by H / R, relieve the pathological injury of kidney and delay the development of acute kidney injury to chronic kidney disease, so that the ginsenoside Rb1 can be used for preparing the medicine for delaying the development of acute kidney injury to chronic kidney disease. Therefore, the progress of AKI to CKD is delayed.

The invention relates to compositions comprising a microRNA having a pro-angiogenic effect. In particular, the invention relates to a composition comprising a microRNA selected from hsa-miR-4691-5p, hsa-miR-4496, hsa-miR-582-5p, and hsa-miR-345-3p. The invention further relates to nucleic acid molecules encoding at least one of these microRNAs and viral particles capable of expressing these microRNAs in a cell. The invention further relates to the use of these microRNAs, nucleic acid molecules or viral particles as medicine, particularly in the treatment of a cardiovascular disease.

The invention discloses a traditional Chinese medicine coated granulation-promoting repair agent for treating diabetic foot ulcer, and belongs to the technical field of traditional Chinese medicine external preparations. Aiming at the defects that existing related preparations are poor in fitting property, uneven in drug release and incapable of meeting stepped treatment requirements, the invention selects seven traditional Chinese medicines of dragon's blood, angelica sinensis, honeysuckle, fructus forsythiae, safflower carthamus, astragalus membranaceus and rhizoma bletillae for compatibility, constructs a synergistic system for clearing away heat and toxic materials, promoting blood circulation to remove blood stasis, tonifying qi and promoting tissue regeneration, and adopts gradient extraction of alcohol extraction and water extraction. The preparation method comprises the following steps: taking process enriched effective components; carrying out ultrasonic dispersion; taking polyvinyl alcohol bletilla gum as a composite film-forming material; and matching with glycerol and polysorbate-80 to prepare the film agent. The repairing agent can be stably attached to a wound surface, realizes uniform and continuous release of a drug, can accurately match a stepped repairing process for removing necrotic tissue, activating blood and promoting granulation, has a wound healing rate of 85% or more after 20 days of treatment, has significant anti-inflammatory and angiogenesis promoting effects, has good dosage form stability and no obvious irritation, is convenient to use, and can promote patients. Due to compliance, wound infection and amputation risks can be reduced, and the external application medicine is suitable for external treatment of diabetic foot ulcer.

The present invention relates to a drug delivery and preparation method for tissue regeneration and treatment through the promotion of angiogenesis, comprising synthesizing various kinds of hyaluronic acid derivatives, and delivering the hyaluronic acid derivatives by using Pluronic F127, which is a temperature-sensitive polymer. More specifically, angiogenesis efficacy of the hyaluronic acid derivatives was analyzed by introducing ethylene diamine, hexamethylene diamine, decane diamine, and gallic acid into hyaluronic acid. As a result of analyzing the angiogenesis effect thereof through an in ovo chick chorioallantoic membrane (CAM) assay, the synthesized hyaluronic acid derivatives exhibited an enhanced angiogenic effect compared to an untreated group or a group treated with hyaluronic acid alone. It is considered that the hyaluronic acid derivatives can be utilized in various medical engineering fields requiring new blood vessel regeneration such as those of damaged tissue or organ regeneration, and cell therapy.

The invention discloses a method for evaluating an angiogenesis effect under the action of TSLP. The method comprises the following steps: enhancing data acquisition and preprocessing of a CT image; the preprocessed data are used for two-dimensional projection and labeling of blood vessels; the marked two-dimensional projection image and depth information are used for depth mapping and partial three-dimensional reconstruction; taking the partially reconstructed blood vessel surface model as input, and performing local feature extraction and label propagation; local features are used for global structure repairing; the globally repaired blood vessel three-dimensional model is used for evaluating the angiogenesis effect; the angiogenesis effect evaluation comprises quantitative evaluation and visual evaluation. According to the invention, artificial intelligence and medical technology are comprehensively utilized, and a comprehensive and fine angiogenesis effect evaluation method is provided.